Expert Perspectives: Orca-T Conditioning Regimens

EP: 1.AlloHSCT in AML: When, Why, and for Whom?

EP: 2.Timing and Candidacy for AlloHSCT in MDS

EP: 3.Optimizing AlloHSCT Timing in ALL & MF: Identifying the Right Candidates

EP: 4.Balancing Cure and Toxicity: Tailoring AlloHSCT Intensity and Timing

EP: 5.Managing GVHD: Incidence and Prophylaxis Strategies After AlloHSCT

EP: 6.EBMT 2025 Spotlight: Long-Term Outcomes With PTCy – Insights From the ALWP-EBMT

EP: 7.EBMT 2025 Highlight: Real-World GVHD Prophylaxis: - Insights From the GETH/TC Group Study

EP: 8.Identifying Appropriate Patients for PTCy as GVHD Prophylaxis in AlloHSCT

EP: 9.Evolving GVHD Prophylaxis: Emerging Drug and Graft Engineering Strategies

EP: 10.Orca-T: A New Allogeneic Cell Therapy - Defining Orca-T and Potential Advantages Compared With Conventional AlloHSCT

EP: 11.EBMT 2025 Spotlight: Key Takeaways From the ORCA-T Phase 3 Trial – Efficacy, Safety, and Insights

EP: 12.EBMT 2025 Highlight: Comparing Orca-T and PTCy – Insights From the Phase 1b Orca-T and Registry-Based PTCy Patients

EP: 13.Orca-T and the Future of AlloHSCT: Addressing Unmet Needs

Now Viewing

EP: 14.Expert Perspectives: Orca-T Conditioning Regimens

Summary for Physicians: Patient Eligibility for ORCA-T vs Conventional AlloHSCT

The discussion focused on how patient eligibility for ORCA-T might differ from conventional alloHSCT, as follows:

• Eligibility changes: ORCA-T may expand eligibility criteria to include patients who are typically considered high-risk for traditional alloHSCT due to lower toxicity and improved safety profile.
• Key differences: Compared with conventional alloHSCT, ORCA-T may allow for a broader range of patients, including those with comorbidities or those previously excluded from standard regimens, to be eligible.

In summary, ORCA-T could potentially broaden the pool of eligible patients, offering treatment to those who may not be candidates for conventional alloHSCT.

Nelli Bejanyan reports consulting or advisory role for CareDx, Medexus Pharmaceuticals, Orca Biosystems, AlloVir, TScan Therapeutics, and Pfizer; and research funding from CRISPR Therapeutics. Everett Meyer reports sponsored research from Orca Biosciences, Kyverna; and a scientific advisor role and equity holder for GigaMune, Indee, TRACT, Jura Biosciences.Caspian Oliai reports no relevant disclosures (investigator on the Orca T trial funded by Orca Biosciences). Arpita P. Gandhi reports roles with OncLive, MJH Life Sciences, OrcaBio (research), CareDx (Advisory Board). Amandeep Salhotra reports received funding from Rigel, Bristol Myers Squibb and Orca Biosciences; and speakers bureau for Incyte and Sanofi.